Evive Biotech: Develop Novel Therapies for Patients Worldwide

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

NEWS LIST

Yifan Pharma Subsidiary Evive Biotech Announce the China NMPA Approval of Ryzneuta™ (Efbemalenograstim alfa Injection) for Chemotherapy-Induced Neutropenia
May 09, 2023
Evive Biotech Enters License Agreement with Acrotech Biopharma to Commercialize Ryzneuta™ in the United States
Nov 22, 2022
Evive Biotech and APOGEPHA Announce Collaboration to Market Efbemalenograstim alfa (F-627) in Germany and Switzerland
Jul 04, 2022

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.